8FL1 image
Entry Detail
PDB ID:
8FL1
EMDB ID:
Keywords:
Title:
Cryo-EM Structure of PG9RSH DU025 Fab in complex with BG505 DS-SOSIP.664
Biological Source:
Host Organism:
PDB Version:
Deposition Date:
2022-12-21
Release Date:
2023-05-31
Method Details:
Experimental Method:
Resolution:
3.75 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Envelope glycoprotein gp41
Chain IDs:A, B, D (auth: F)
Chain Length:153
Number of Molecules:3
Biological Source:Human immunodeficiency virus 1
Polymer Type:polypeptide(L)
Description:Envelope glycoprotein gp120
Chain IDs:C, E (auth: G), F (auth: I)
Chain Length:481
Number of Molecules:3
Biological Source:Human immunodeficiency virus 1
Polymer Type:polypeptide(L)
Description:PG9 DU025 Heavy
Chain IDs:G (auth: H)
Chain Length:248
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:PG9 DU025 Light
Chain IDs:H (auth: L)
Chain Length:216
Number of Molecules:1
Biological Source:Homo sapiens
Ligand Molecules
Primary Citation
Improved HIV-1 neutralization breadth and potency of V2-apex antibodies by in silico design.
Cell Rep 42 112711 112711 (2023)
PMID: 37436900 DOI: 10.1016/j.celrep.2023.112711

Abstact

Broadly neutralizing antibodies (bNAbs) against HIV can reduce viral transmission in humans, but an effective therapeutic will require unusually high breadth and potency of neutralization. We employ the OSPREY computational protein design software to engineer variants of two apex-directed bNAbs, PGT145 and PG9RSH, resulting in increases in potency of over 100-fold against some viruses. The top designed variants improve neutralization breadth from 39% to 54% at clinically relevant concentrations (IC80 < 1 μg/mL) and improve median potency (IC80) by up to 4-fold over a cross-clade panel of 208 strains. To investigate the mechanisms of improvement, we determine cryoelectron microscopy structures of each variant in complex with the HIV envelope trimer. Surprisingly, we find the largest increases in breadth to be a result of optimizing side-chain interactions with highly variable epitope residues. These results provide insight into mechanisms of neutralization breadth and inform strategies for antibody design and improvement.

Legend

Protein

Chemical

Disease

Primary Citation of related structures